NASDAQ$GEHC
GE HealthCare Technologies Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
GE HealthCare reported strong revenue growth across all business segments and regions due to easing supply chain challenges, with price and productivity positively impacting margin performance.
GE HealthCare reported a revenue of $4.7 billion, an 8% increase year-over-year. Net income attributable to GE HealthCare was $372 million, and adjusted EPS was $0.85. The company reaffirmed its full-year 2023 guidance, expecting 5% to 7% organic revenue growth.
- Revenue increased by 8% year-over-year, with organic revenue growth of 12%.
- Net income attributable to GE HealthCare was $372 million, while adjusted EBIT reached $664 million.
- Diluted EPS was $0.41, and adjusted EPS was $0.85.
- The Board of Directors declared a cash dividend of $0.03 per share for the first quarter of 2023.
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$4.71B
Revenue by segment
GE HealthCare · $3.85B total across 4 segments · Q1 2023
- Imaging$2.5B+8.2%64.9%
- Patient Care$781M+9.1%20.3%
- Pharma Diagnostics$558M+15.3%14.5%
- Other$13M-23.5%0.3%
Forward guidance
The Company reaffirmed its guidance for full year 2023:
Tailwinds
- Organic revenue growth in the range of 5% to 7% year-over-year.
- Adjusted EBIT margin in the range of 15.0% to 15.5%, reflecting an expansion of 50 to 100 basis points versus 2022 Standalone Adjusted EBIT margin of 14.5%.
- Adjusted effective tax rate (ETR) in the range of 23% to 25%.
- Adjusted EPS in the range of $3.60 to $3.75, representing 7% to 11% growth. This compares to 2022 Standalone Adjusted EPS of $3.38.
- Free cash flow conversion of 85% or more for the full year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2023
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro